EMIT II Plus Buprenorphine Assay

No cross-reactivity to commonly abused opiates

The EMIT® II Plus Buprenorphine Assay is intended for the qualitative and semiquantitative analysis of buprenorphine in human urine at a cutoff value of 5 ng/mL.

Contact Us

Features & Benefits

Buprenorphine is a semisynthetic opiate that has powerful analgesic capabilities and is approximately 25–40 times as potent as morphine. Buprenorphine is used as a substitution drug for opioid addiction treatment but has a high potential for abuse and addiction.

The EMIT II Plus Buprenorphine Assay provides:

  • High specificity for buprenorphine and norbuprenorphine
  • No cross-reactivity to buprenorphine glucuronide or norbuprenorphine glucuronide
  • No cross-reactivity relative to common interferants such as riboflavin
  • Ready-to-use liquid reagents, calibrators, and controls
  • ≥90% agreement to LC-MS/MS


Applications are available for the Viva-Jr®, Viva-E®, Viva-ProE®, V-Twin® drug testing systems and AU® Series analyzers.

 

Technical Specifications

 Assay Principle

  Homogeneous Enzyme Multiplied Immonoassay (EMIT)

 Cut-off

  5 ng/mL

 Sample

  Urine  

 Reagent Stability

  Unopened: until expiration date. Onboard instrument: up to 4 weeks

 Calibration Frequency

  As indicated by control results